AtriCure Q4 revenue $124.3M (+16.6% YoY); guides FY25 rev $517-527M

AtriCure, Inc.

2024-FY EPS reported -$0.95 revenue$465,307,000

Q4 revenue $124.3M (+16.6%); full year revenue $465.3M (+16.5%).
Q4 GAAP net loss $0.33/sh; adj. loss $0.08/sh; adj. EBITDA positive $12.7M.
Full year 2024 adj. EBITDA $31.1M (vs $19.4M in 2023); adj. loss $0.67/sh (vs $0.75).
Launched cryoSPHERE+, cryoSPHERE MAX, AtriClip FLEX-Mini in US, EnCompass clamp in Europe.
FY2025 guidance: rev $517-527M; adj. EBITDA $42-44M; adj. loss $0.57-0.64/sh.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.